The National Institutes of Health announced an immediate policy ending the use of human fetal tissue in all NIH-supported research, applying across federal programmes and funding mechanisms.
The decision was set out in a formal notice issued in the United States on 22 January 2026 by the NIH and its Director, Jay Bhattacharya. The policy matters because it changes eligibility for federal biomedical funding and directs research toward alternative scientific models.
The National Institutes of Health released the policy through an official funding notice and Director’s statement, positioning the change as part of a broader effort to modernise federally supported biomedical research. The announcement applies nationwide and affects both internal NIH research and projects supported through federal grants and contracts.
Policy Announcement and Scope
The National Institutes of Health stated that, effective immediately, NIH funds will no longer be used to support research involving human fetal tissue obtained from elective abortions. The policy applies to the NIH Intramural Research Program and all NIH-supported extramural research, including grants, cooperative agreements, other transaction awards, and research and development contracts.
Additionally, the NIH said the updated guidance supersedes prior policies and establishes a single standard across all federally funded biomedical projects under its authority. The notice was issued through the NIH Grants and Funding system and the Office of the NIH Director.
Elements of the NIH Policy
| Indicator | Recent Movement | Context |
|---|---|---|
| Policy status | Implemented immediately | NIH Grants Notice states the change takes effect upon publication by the National Institutes of Health |
| Research scope | All NIH-supported programmes | Applies to intramural research and extramural funding, including grants and contracts, as outlined by NIH |
| Funding eligibility | Human fetal tissue projects excluded | NIH Director’s statement confirms federal funds will no longer support this category of research |
Progress Timeline
| Date | Event | Key Details | Citation |
|---|---|---|---|
| June 5, 2019 | Trump 1.0 intramural ban | HHS halts fetal tissue use at NIH campuses; new ethics board for grants | |
| July 2019 | Extramural rules detailed | 6-month reviews required; new cell lines banned; research declines | |
| April 15–16, 2021 | Biden reversal (NOT-OD-21-111) | Lifts intramural ban, scraps ethics board, eases extramural access | |
| FY2024 | Usage hits low | 77 projects funded (~$53M), down sharply since 2019 | |
| January 21–22, 2026 | Trump 2.0 full ban (NOT-OD-26-028) | Bans all NIH funding for elective abortion fetal tissue; immediate effect | |
| 2026 onward | Reb budgeting & future | Existing grants pivot; public comment on stem cell alternatives planned |
Funding Rules and Research Activities Affected
The NIH said the policy change affects eligibility for a wide range of federal funding mechanisms, including cooperative agreements, other transaction awards, and research and development contracts. Projects involving human fetal tissue will no longer qualify for NIH financial support under the revised framework.
Meanwhile, the agency confirmed that existing guidance is replaced by the new policy, creating a uniform funding standard across its 27 Institutes and Centers. The NIH noted that the change is intended to align funding decisions with current federal research priorities.
Funding Coverage Overview
| Indicator | Recent Movement | Context |
|---|---|---|
| Grants | Eligibility revised | NIH funding rules exclude projects using human fetal tissue, per official notice |
| Contracts | Scope expanded | Research and development contracts are included in the policy, according to NIH |
| Agreements | Unified standard applied | Cooperative agreements and transaction awards now follow the same funding restriction |
Statement from NIH Leadership
NIH Director Jay Bhattacharya said the decision reflects a move toward research methods that can better model human health and disease. He described the policy as part of a broader effort to direct federal resources toward emerging scientific platforms.
Additionally, the Director linked the funding change to what he described as taxpayer stewardship and alignment with current scientific capabilities. The statement was released through the official NIH website alongside the funding notice.
- Leadership position: Jay Bhattacharya, NIH Director, said the policy is intended to invest in “breakthrough technologies,” according to the NIH Director’s public statement
Shift Toward Alternative Research Models
The NIH cited advances in organoids, tissue chips, computational biology, and related platforms as alternatives to research using human fetal tissue. The agency said these technologies have expanded in recent years and can support biomedical discovery under the updated policy framework.
Meanwhile, the NIH reported that projects using human fetal tissue have declined since 2019, with only 77 such projects funded in Fiscal Year 2024. The figure was published by the NIH as part of the policy announcement materials.
- Technology focus: Organoids, tissue chips, and computational biology referenced as validated alternatives by the NIH
- Funding trend: NIH reports 77 projects using human fetal tissue funded in Fiscal Year 2024
Public Engagement and Future Reviews
The NIH said it will seek public comment on the robustness of emerging biotechnologies, including their potential to reduce reliance on human embryonic stem cells. The agency stated that feedback will inform future assessments of research modernisation.
Additionally, the NIH said it will continue to engage the scientific community to identify further areas where federal research policy can be updated. The process will be conducted through formal notice and comment channels managed by the Department of Health and Human Services.
Bottom Line
The National Institutes of Health has introduced an immediate funding policy ending the use of human fetal tissue in all NIH-supported research. The change applies across intramural and extramural programmes and redirects federal support toward alternative biomedical models.
NIH leadership said the update is part of a wider effort to modernise research practices while maintaining oversight of public funding and engagement with the scientific community.
Sources: National Institutes of Health Grants Notice, and NIH Director Statement.
Prepared by Ivan Alexander Golden, Founder of THX News, an independent news organization delivering timely insights from global official sources.
Combines AI-analyzed research with human-edited accuracy and context.
